TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Murphy, Kristen L.
A1  - Kittrell, Frances S.
A1  - Gay, Jason P.
A1  - Jäger, Richard
A1  - Medina, Daniel
A1  - Rosen, Jeffrey M.
T1  - Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice
JF  - Oncogene
N2  - Bcl-2 is known to have dual antiproliferative and antiapoptotic roles. Overexpression of Bcl-2 in the mammary gland using a whey acidic protein (WAP) promoter-driven Bcl-2 transgene inhibits apoptosis in the mammary gland during pregnancy, lactation, and involution, and also counteracts apoptosis induced by overexpression of a mutant p53 transgene (WAP-p53 172 R-L). WAP-Bcl-2 mice and nontransgenic controls were treated with the carcinogen dimethylbenz(a)anthracene (DMBA). Surprisingly, the nontransgenic mice developed mammary tumors with decreased latency. Tumors arising in WAP-Bcl-2 mice displayed substantially reduced levels of proliferation relative to those seen in nontransgenic mice (P < 0.015), perhaps resulting in the observed increase in tumor latency following carcinogen treatment. This WAP-Bcl-2 mouse tumor model reflects the situation seen in some human breast cancers overexpressing Bcl-2, where expression of Bcl-2 has been shown to correlate with a lower proliferative index in tumors.
SN  - 0950-9232
SS  - 0950-9232
U6  - https://doi.org/10.1038/sj.onc.1203099
DO  - https://doi.org/10.1038/sj.onc.1203099
VL  - 18
IS  - 47
SP  - 6597
EP  - 6604
PB  - Nature Publishing Group
ER  -